Novo Nordisk Launches Oral Wegovy for Self-Pay Patients at $149

Novo Nordisk began offering its oral Wegovy (semaglutide) pill to self‑pay patients in the United States on Jan. 5, 2026, setting introductory cash prices at $149 per month for the lower doses and $299 per month for the highest strengths. The company made the product available under the Wegovy brand after the U.S. Food and Drug Administration approved the oral formulation on Dec. 22, 2025.

The initial pricing structure makes the 1.5 mg and 4 mg once‑daily tablets available at $149 per month through April 15, 2026, while 9 mg and 25 mg doses are being offered at $299 per month. Novo Nordisk plans to raise the cash price for the 4 mg dose to $199 per month on April 15, 2026. The company is offering the pills through broad retail and delivery channels, with self‑pay purchasing available at more than 70,000 pharmacies nationwide as well as through home delivery services and select telehealth providers. NovoCare Pharmacy, a company program, will support cash‑pay patients with home shipments, benefit verification, refill reminders and access to live support from case managers.

The oral pill contains the same active ingredient as injectable Wegovy and Ozempic. Promotional materials cited by partners note clinical trial results showing average weight loss of 13.6 percent (about 31.3 pounds) at 64 weeks for users of the 25 mg oral dose, and 14.9 percent (about 33.6 pounds) at 68 weeks for users of a 2.4 mg injectable dose. Novo Nordisk has positioned the oral product as offering comparable weight‑loss results to the injectable option, while providing a daily pill alternative to injections.

The move to sell an oral formulation directly to cash‑pay consumers follows earlier promotional pricing for injectables. In a company release dated Nov. 17, 2025, Novo Nordisk announced limited‑time self‑pay pricing changes for injectable products, offering certain starter doses and competitor products at reduced prices for new self‑pay patients and cutting existing self‑pay prices for Wegovy and Ozempic. Those injectable promotions are distinct in timing and scope from the oral pill launch.

Industry analysts say the oral approval and retail launch could give Novo Nordisk a commercial boost as it seeks to regain market ground against rivals in the fast‑growing GLP‑1 weight‑loss market. At the same time, the company’s initial offers apply only to self‑pay customers; material from partner programs notes patients enrolled in government‑funded healthcare programs are not eligible for some promotional prices. Insurer coverage for oral Wegovy remains uncertain and could determine whether broad patient access is sustained once introductory pricing windows close.

Physicians and public‑health experts caution that lower out‑of‑pocket prices may expand access but will not resolve longer‑term questions about treatment duration, monitoring, and equity. As the oral pill reaches pharmacies and telehealth channels, regulators, insurers and clinicians will be watching whether reduced cash prices translate into sustained, medically appropriate use rather than short‑term demand spikes driven by affordability alone.